A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation

American Heart Journal

Volumn 152, Issue 4, 2006, Pages 761.e1-761.e6

  Radke, Peter W ^a   Figulla, Hans R ^b   Drexler, Helmut ^c   Klues, Heinrich G ^d   Mügge, Andreas ^e   Silber, Sigmund ^f   Daniel, Werner ^g   Schmeisser, Alexander ^h   Reifart, Nicolaus ⁱ   Motz, Wolfgang ^j   Büttner, Hans Joachim ^k   Fischer, Dieter ^c   Ortlepp, Jan R ^a   Schaefers, Kerstin ^a   Hoffmann, Rainer ^a   Hanrath, Peter ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Department of Cardiology ^*  (Germany)

^d Klinikum Krefeld   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Klinik Dr Mueller   (Germany)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁱ Kardiologisches Institut   (Germany)

^j Heart Center Karlsburg   (Germany)

^k UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ANGIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG SCREENING; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; IMPLANTATION; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SEX RATIO; STATISTICAL SIGNIFICANCE;

EID: 33748847735     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.07.003     Document Type: Article

References (22)

1. Bhargava B., Kathrikeyan G., Abizaid A.A., et al. New approaches to preventing restenosis. BMJ 327 (2003) 274-279
2. Langeveld B., Roks A.J.M., Tio R.A., et al. Renin-angiotensin system interventions to prevent in-stent restenosis. J Cardiovasc Pharmacol 45 (2005) 88-89
3. Peters S., Gotting B., Trummel M., et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 13 (2001) 93-97
4. Yoshida O., Hirayama H., Nanasato M., et al. The angiotensin II receptor blocker candesartan cilexetil reduced neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J 149 (2005) e1-e6
5. Wakeyama T., Ogawa H., Iida H., et al. Affects of candesartan and probucol on restenosis after coronary stenting. Results of stent intimal hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 67 (2003) 519-524
6. Prati F., Pawlowski T., Sommariva L., et al. Intravascular ultrasound and quantitative coronary angiography assessment of late in-stent restenosis: in vivo human correlation and methodological implications. Catheter Cardiovasc Interv 57 (2002) 155-160
7. Sütsch G., Büchi M., Zeiher A.M., and for the ENCORE II study group. Evaluation of nifedipine and cerivastatin on recovery of endothelial function II. Eur Heart J 1 Suppl M (1999) M27-M32
8. vom Dahl J., Haager P.K., Grube E., et al. Effects of gold coating of coronary stents on neointimal proliferation following stent implantation. Am J Cardiol 89 (2002) 801-805
9. Ohishi M., Ueda M., Rakugi H., et al. Expression of angiotensin II type I and type II receptors in the neointima at the site of percutaneous transluminal coronary angioplasty in humans. Hypertension 28 (1996) 529
10. Forrester J.S., Fishbein M., Helfant R., et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 17 (1991) 758-769
11. Kawamura M., Terashita Z., Okuda H., et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 266 (1993) 1664-1669
12. Kauffman R.F., Bean J.S., Zimmerman K.M., et al. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury in rats. J Pharmacol Exp Ther 226 (1993) 1664-1669
13. Miyazaki M., Wada T., Shiota N., et al. Effect of angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens 13 Suppl. 1 (1999) S 21-S 25
14. Wilson D.P., Saward L., Zahradka O., et al. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 42 (1999) 761-772
15. Powell J.S., Clozel J.P., Muller R.K., et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245 (1989) 186-188
16. Huber K.C., Schwartz R.S., Edwards W.D., et al. Effects of angiotensin converting enzyme inhibitors on neointimal proliferation in a porcine coronary injury model. Am Heart J 125 (1993) 695-701
17. Huckle W.R., Drag M.D., Acker W.R., et al. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation 93 (1996) 1009-1019
18. Schwartz R.S., Chronos N., and Virmani R. Preclinical models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 44 (2004) 1373-1385
19. Elezi S., Kastrati A., Pache J., et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 33 (1998) 1866-1873
20. Walter D.H., Schachinger V., Elsner M., et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85 (2000) 962-968
21. Walton B.L., Mumm K., Taniuchi M., et al. Diabetic patients treated with abciximab and intracoronary stenting. Catheter Cardiovasc Interv 55 (2002) 321-325
22. Mintz G.S., Hong M.K., Raizner A.E., et al. Comparison of quantitative angiographic parameters with the magnitude of neointimal hyperplasia measured by volumetric intravascular ultrasound in patients treated with bare metal and nonpolymeric paclitaxel-coated stents. Am J Cardiol 95 (2005) 105-107